Enfermedades neurológicas y psiquiátricas en el anciano

Références bibliographiques

• Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E. Range of neuropsychiatric disturbances in patients with Parkinson Disease. J Neurol Neurosurg Psychiatry. 1999;67:492-6.
• Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P. Quality of life in dementia: more than just cognition. An analisys of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry. 2006;77:146-8.
• Braak H, del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197-211.
• Buter TC, Van Den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival on Parkinson disease: a 12 year population study. Neurology. 2008;70(13):1017-22.
• Canovas P, García-Arilla Calvo E, Sanjoaquín Romero AC, Alarcón Co-rominas J. Delirium en ancianos hospitalizados. Med Clin. 2008;130(17): 679.
• Casado I, Calatayud T. Epidemiología y factores de riesgo. Guía oficial para la práctica clínica en demencias: conceptos, criterios y recomendaciones. Barcelona: Prous Science; 2009. p. 23-50.
• Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119(6): 737-54.
• Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40:23-9.
• Constantinescu R, Mondello S. Cerebrospinal fluid biomarker candidates for Parkinsonian disorders. Front Neurol. 2013;3:187.
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory. Comprehensive assessment of psychopatology in dementia. Neurology. 1994;44:2308-14.
• Dewing P, Chiang CW, Sinchak K, Sim H, Fernagut PO, Kelly S. Direct regulation of adult brain function by the male specific factor SRY. Curr Biol. 2006;16:415-22.
• Dubois B, Burn D, Goetz C. Diagnostic procedures for Parkinson disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord. 2007;15:22
• Eeles EM, Hubbard RE, White SV, O'Mahony MS, Savva GM, Bayer AJ Hospital use, institutionalisation and mortality associated with delirium. Age and Ageing. 2010;39(4):470-5.
• Elie D. Using psychostimulants in end of life patients with hypoactive delirium and cognitive disorders: A literature review. Can J Psychiatry. 2010;55(6):386-93.
• Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer’s disease. BMC Medicine. 2010;8:89-102.
• Formiga F, Riera-Mestre A, Chivite D, Pujol R. Delirium en pacientes mayores de 94 años con fractura de fémur. Rev Esp Geriatr Gerontol. 2008;43:154-6.
• García Alberca JM, Lara JP, González Barón S, Barbancho MA, Porta D, Berthier M. Prevalencia y comorbilidad de síntomas neuropsiquiátricos en la enfermedad de Alzheimer. Actas Esp Psiquiatría. 2008;36:265-70.
• Garnica Fernández A. Tratamiento no farmacológico de la Enfermedad de Parkinson en el anciano. Guía de buena práctica clínica en Geriatría. Enfermedad de Parkinson. Barcelona: SEGG, Elsevier Doyma; 2009. p. 73-85.
• Gazewood JD, Richards DR, Clebak K. Parkinson disease: an updated. Am Fam Physician. 2013;87(4):267-73.
• Gilman S. Parkinsonian syndromes. Clin Geriatr Med. 2006;22:827-42.
• Goldman JS, MPhil MS, Hahn SE, LaRusse-Eckert S, Butson MB, Rumbaugh M. Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6): 597-605.
• González M, de Pablo J, Fuente E, Valdés M, Peri JM, Nomdedeu M. Instrument for detection of delirium in general hospitals: adaptation of the confusion assessment method. Psychosomatics. 2004;45(5):426-31.
• González Glaría B. Enfermedad de Parkinson y otros parkinsonismos. Tratado de Neuropsicogeriatría. Madrid: SEGG; 2010. p. 214-38.
• Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF. Classiffication of primary progressive aphasia and its variants. Neurology. 2011;76:1006-14.
• Griffith HR, Stewart CC, Den Hollander JA. Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. International Review of Neurobiology. 2009;84:105-31.
• Grossman M. Multimodal comparative studies of neurodegenerative diseases. J Alzheimers Dis. 2013;33(01):S379-83.
• Hermann N, Black S, Li A, Lanctot KL. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. Int Psychogeuratr. 2011:23(4):539-45.
• Inouye SK. Delirium in older persons. N Eng J Med. 2006;354:1157:65.
• Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012;27:8.
• Kieburtz K, Wunderle KB. Parkinson’s disease: evidence for environmental risk factors. Mov Disord. 2013;28:8.
• Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Neurología. 2013;28(8):503-21.
• Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. The Lancet. 2013;383:828-40.
• Marín Carmona M, Álvarez Fernández B. Demencia tipo Alzheimer. Tratado de neuropsicogeriatría. Madrid: SEGG; 2010. p. 214-238.
• Mass A, Reichmann H. Sleep and non-motor symptoms in Parkinson’s disease. J Neural Transm. 2013;120:565-9.
• Massoud F, Gauthier S. Update on the pharmacological treatment for Alzheimer’s Disease. Current Neuropharmacology. 2010;8:69-80.
• McKeith I, Cummings JL. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005;4:735-42.
• Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996-1002.
• Molinuevo JL. Papel de los biomarcadores en el diagnóstico precoz de la enfermedad de Alzheimer. Rev Esp Geriatr y Gerontol. 2011:46Supl1:39-41.
• Molinuevo JL. Memantina: el valor de la terapia combinada. Rev Neurol. 2011;52(2):95:100.
• Muller T. Drug therapy in patients with Parkinson’s disease. Translational Neurodegenerative. 2012;1:10-22.
• Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72:893.
• Oldenbeuving AW, de Kort PL, Jansen BP, Kappelle LJ, Roks G. A pilot study of rivastigmine in the treatment of delirium after a stroke: a safe alternative. BMC Neurol. 2008;20(8):34.
• Osing C, Reichmann H. Treatment of Parkinson’s disease in the advanced stage. J Neurol Transm. 2013;120:523-9.
• Panegyres PK, Frencham K. Course and causes of suspected dementia in young adults: a longitudinal study. Am J Alzheimer’s Dis Other Deme. 2007;22(1):48-56.
• Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease. Drugs Aging. 2011;1;28(7):539-46.
• Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ. Mild cognitive impairment: ten years later. Arch Neu-rol. 2009;66(12):1447-55.
• Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural variant frontotemporal dementia: diagnosis, clinical staging and management. Lancet Neurol. 2011;10:162-72.
• Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, Weintraub D. Diagnosis and management of Parkinson’s disease dementia. Int J Clin Pract. 2008;62(10):1581-7.
• Popeo DM. Delirium in older adults. Mt Sinai J Med. 2011;78(4):571-82.
• Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson’s disease. Mov Disord. 2012;27:831.
• Reisberg B, Doody R, Soffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate to severe Alzheimer’s Disease. N Engl J Med. 2003;348: 1333-41.
• Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012;43:600-8.
• Vidán MT, Sánchez E, Alonso M, Montero B, Ortiz J, Serra A. An intervention integrated into daily clinical practice reduces the incidence of delirium during hospitalization in elderly patients. J Am Geriatr Soc. 2009;57:2029-36.
• Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syn-dromes. BMC Neurology 2007;7:27-39.
• Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M. Recommendations for diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:1-26.
• Weimer D, Sager MA. Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes. Alzheimer Dement. 2009;5(3):215-26.
• Weintrraub D, Hurtig H. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164:1491-8.
• Wong CL. Does this patient have delirium? Value of bedside instruments. JAMA. 2010;304(7):779-86.
• Young J, Inouye S. Delirium in older people. Clinical Review. BMJ. 2007;334:842-6.
• Young J, Murthy L, Westby M, Akunne A, O’Mahony R; Guideline Development Group. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ. 2010;28(341):3704.